Intranasal Vasopressin Treatment in Children With Autism

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

157

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

March 18, 2024

Study Completion Date

March 18, 2024

Conditions

AutismAutism Spectrum DisorderASD

Interventions

DRUG

Vasopressin (USP) Injectable Solution [Vasostrict]

Nasal Spray

DRUG

Placebo

Placebo Nasal Spray

Trial Locations (1)

Stanford University, Stanford

All Listed Sponsors

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Stanford University

OTHER

NCT03204786 - Intranasal Vasopressin Treatment in Children With Autism | Biotech Hunter | Biotech Hunter